Evidence map›Paper›PMID 35966592›Full record

ArticleTheranostics2022

Translational immunoPET imaging using a radiolabeled GD2-specific antibody in neuroblastoma.

Julia Schmitt, Johannes Schwenck, Andreas Maurer, Mirko Przybille, Dominik Sonanini, Gerald Reischl, Jöri E Wehrmüller, Leticia Quintanilla-Martinez, Stephen D Gillies, Marcel A Krueger and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Review
  3. Mapping the knowledge landscape of the PET/MR domain: a multidimensional bibliometric analysis.European journal of nuclear medicine and molecular imaging · 2025
    Review
  4. Theranostics for Neuroblastoma: Making Molecular Radiotherapy Work Better.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Advances in PET imaging of cancer.Nature reviews. Cancer · 2023
    Review
  13. First-in-Humans PET/MRI of In Vivo GD2 Expression in Osteosarcoma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023
    Article
  14. Imaging Techniques in Pharmacological Precision Medicine.Handbook of experimental pharmacology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 3 countries.

Julia SchmittWerner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tuebingen, Germany.
Johannes SchwenckWerner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tuebingen, Germany.
Andreas MaurerWerner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tuebingen, Germany.
Mirko PrzybilleWerner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tuebingen, Germany.
Dominik SonaniniWerner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tuebingen, Germany.
Gerald ReischlWerner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tuebingen, Germany.
Jöri E WehrmüllerCenter for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen, Switzerland.
Leticia Quintanilla-MartinezInstitute of Pathology and Neuropathology, University Hospital Tuebingen, Eberhard Karls University Tuebingen, Germany.
Stephen D GilliesProvenance Biopharmaceuticals Corp., Carlisle, MA, USA.
Marcel A KruegerWerner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tuebingen, Germany.
Juergen F SchaeferDepartment of Diagnostic and Interventional Radiology, Eberhard Karls University Tuebingen, Germany.
Christian la FougèreDepartment of Nuclear Medicine and Clinical Molecular Imaging, Eberhard Karls University Tuebingen, Germany.
Rupert HandgretingerChildrens Hospital, Department of Hematology and Oncology, Eberhard Karls University Tuebingen, Germany.
Bernd J PichlerWerner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tuebingen, Germany.
Siemens (Germany) · DEUniversity of Tübingen · DEGuided Therapeutics (United States) · USGerman Cancer Research Center · DEHeidelberg University · DEPaul Scherrer Institute · CHscPharmaceuticals (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

GangliosidesNeuroblastomaAnimalsChelating AgentsCHO CellsCricetinaeCricetulusHEK293 CellsHumansMiceChelating AgentsGangliosidesGD2ImmuneImagingneuroblastomaPETtheranostic

Identifiers

PMID35966592
PMCPMC9373823
OpenAlexW4285819180

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.